news
Immunotherapy treatment enhances lymphoma survival, landmark study shows
The Phase III findings give evidence for the immunotherapy treatment regimen to become standard of care for advanced Hodgkin lymphoma.
List view / Grid view
doxorubicin
article
Advancing NOX inhibitors for treating fibrotic diseases and cancer
This article explores the benefit of NOX inhibitors for fibrotic diseases and cancers and highlights the potential of Calliditas Therapeutics’ drug setanaxib, including its application in wider related indications.
news
FDA approves first new B-cell lymphoma treatment in 20 years
A first-line B-cell lymphoma treatment shown to reduce the risk of disease progression or relapse by 27 percent has been approved by the FDA.
news
Biohybrid microrobots could be effective cancer drug delivery systems
A new study demonstrates the design and potential of adding artificial components to bacteria to enable tumour targeted drug release and immune activation.
news
Novel chemotherapeutic pro-drug approved for FIH trial in the UK
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
news
Novel ionic liquid enables uniform chemotherapy delivery in solid tumours
Co-injecting doxorubicin with LATTE, a novel ionic liquid formulation, resulted in uniform chemotherapy delivery and successful ablation in solid tumours.
news
Chemotherapy could lead to mitochondrial dysfunction in skeletal muscle
Chemotherapy drugs commonly used in breast cancer leads to a decrease in muscle mitochondria, and could result in fatigue after treatment...
news
Doxorubicin disrupts the immune system to cause heart toxicity
Doxorubicin induced irreversible dysregulation which decreased the levels of lipoxygenases and cyclooxygenases in the left ventricle...
news
Improved method of delivering anti-cancer drugs
A new non-toxic method for delivering anti-cancer drugs to specific parts of the human body could mean the end of the severe side effects...
news
Functionalizing liposomes could pave the way to personalised medicine
Researchers have shown a method to functionalize liposomes for specific targeting, potentially paving the way for personalised medicine...
news
Next-generation drug testing on chips
Researchers in Japan have designed a small 'body-on-a-chip' device that can test the side effects of drugs on human cells...
news
NICE recommends Lilly’s Olaratumab (Lartruvo) to treat sarcoma
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
news
EC approval for Lilly’s soft tissue sarcoma drug Olaratumab
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
This conditional marketing authorisation is based on data from the Phase 2 portion of the pivotal JGDG trial and followed a positive recommendation from...
news
Combining soft-tissue cancer drugs improves survival
21 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Scientists discovered that adding a novel monoclonal antibody therapy to traditional chemotherapy increased survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer.
news
FDA grants Priority Review for olaratumab BLA
4 May 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.
